Triple Negative Breast Cancer(TNBC) Clinical Trials

37 recruitingLast updated: June 17, 2026

There are 37 actively recruiting triple negative breast cancer(tnbc) clinical trials across 11 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Triple Negative Breast Cancer(TNBC) Trials at a Glance

37 actively recruiting trials for triple negative breast cancer(tnbc) are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in Houston, Shanghai, and Nashville. Lead sponsors running triple negative breast cancer(tnbc) studies include Fudan University, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., and Sun Yat-sen University.

Browse triple negative breast cancer(tnbc) trials by phase

Treatments under study

About Triple Negative Breast Cancer(TNBC) Clinical Trials

Looking for clinical trials for Triple Negative Breast Cancer(TNBC)? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple Negative Breast Cancer(TNBC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple Negative Breast Cancer(TNBC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Not Applicable

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)
Massachusetts General Hospital75 enrolled1 locationNCT07513311
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Triple Negative Breast Cancer(TNBC)HR+ Breast CancerHR+/HER2- Breast Cancer+1 more
NiKang Therapeutics, Inc.361 enrolled14 locationsNCT07029399
Recruiting
Phase 2

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Triple Negative Breast Cancer(TNBC)
The First Affiliated Hospital with Nanjing Medical University58 enrolled1 locationNCT07394387
Recruiting
Phase 2

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Breast CancerNode-positive Breast CancerHER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center32 enrolled1 locationNCT07276880
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Breast CancerTriple Negative Breast Cancer(TNBC)Residual Disease+1 more
UNC Lineberger Comprehensive Cancer Center78 enrolled1 locationNCT07069595
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Head and Neck CancerNon-small Cell Lung CancerTriple Negative Breast Cancer(TNBC)+4 more
Aktis Oncology, Inc.150 enrolled9 locationsNCT07020117
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 1

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

Triple-Negative Breast CancerEndometrial CancerTriple Negative Breast Cancer(TNBC)+3 more
Epsilogen Ltd45 enrolled7 locationsNCT06547840
Recruiting
Phase 2

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Breast CancerTriple Negative Breast Cancer(TNBC)Early Stage Breast Cancer+2 more
Sun Yat-sen University192 enrolled5 locationsNCT06768931
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

HER2-positive Breast CancerTriple Negative Breast Cancer(TNBC)Breast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 3

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer(TNBC)
Akeso416 enrolled1 locationNCT06767527
Recruiting
Phase 2

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)
Affiliated Hospital of Nantong University30 enrolled1 locationNCT07342283
Recruiting
Phase 1

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

Triple Negative Breast Cancer(TNBC)Advanced Solid Tumors Cancer
ProteinQure Inc.80 enrolled4 locationsNCT07190469
Recruiting
Phase 1

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Ovarian CancerCervical CancerEndometrial Cancer+7 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149